University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.
Bit Bio, a UK-based stem cell programming technology spinout of University of Cambridge completed a $41.5m series A round on Saturday co-led by private investors Richard Klausner, Bob Nelsen, and Jim Tananbaum.
The round included venture capital firms BlueYard Capital and Arch Venture Partners as well as healthcare-focused investment firm Foresite Capital. Tananbaum is founder and CEO of Foresite Capital while Nelsen is co-founder and managing director of Arch Venture Partners.
Founded in 2016 as Elpis Biomed, Bit…